Lynch syndrome and MYH-associated polyposis: Review and testing strategy

Journal of Clinical Gastroenterology

Volumn 45, Issue 6, 2011, Pages 488-500

  Goodenberger, McKinsey ^a   Lindor, Noralane M ^b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

DNA mismatch repair; genetic testing; hereditary colorectal cancer; lynch syndrome; MSI; MYH associated polyposis

Indexed keywords

GENE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MYH ASSOCIATED POLYPOSIS SYNDROME; MYH GENE; POLYPOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

CHILD; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA GLYCOSYLASES; DNA MISMATCH REPAIR; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INTESTINAL POLYPOSIS; SYNDROME;

EID: 79958793703     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318206489c     Document Type: Review

References (92)

1. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78-85. (Pubitemid 30451850)
2. Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044-2058.
3. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96:2992-3003. (Pubitemid 32959544)
4. Vasen HF, van der Meulen-de Jong AE, de Vos Tot Nederveen Cappel WH, et al. Familial colorectal cancer risk: ESMO clinical recommendations. Ann Oncol. 2009;20(suppl 4):51-53.
5. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C-T:A mutations in colorectal tumors. Nat Genet. 2002;30:227-232.
6. Hampel H. Genetic testing for hereditary colorectal cancer. Surg Oncol Clin N Am. 2009;18:687-703.
7. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76:1-18.
8. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481-1487. (Pubitemid 28226275)
9. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783-5788.
10. Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet. 2001;69:780-790. (Pubitemid 32868523)
11. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary nonpolyposis cancer). J Med Genet. 2007;44:353-362. (Pubitemid 46953715)
12. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet. 2005;42:491-496. (Pubitemid 40847237)
13. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214-218. (Pubitemid 29144749)
14. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919-932. (Pubitemid 36298000)
15. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010;138:2300-2306.
16. Lin KM, Shashidharan M, Ternent CA, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. 1998;41:428-433. (Pubitemid 28169667)
17. Jass JR, Smyrk TC, Stewart SM, et al. Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res. 1994;14:1631-1634. (Pubitemid 24356996)
18. Thomas BC, Ferber MJ, Lindor NM. DNA mismatch repair and lynch syndrome. In: Potter JD, Lindor NM, eds. Genetics of Colorectal Cancer. New York, NY: Springer Science; 2009.
19. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004;127:17-25. (Pubitemid 38962270)
20. Watson P, Vasen HF, Mecklin JP, et al. The risk of extracolonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444-449. (Pubitemid 351842032)
21. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010;102:193-201.
22. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507-1517. (Pubitemid 44465515)
23. NCCN. NCCN practice guidelines in oncology, Colorectal Cancer Screening. National Comprehensive Cancer Network; 2010.
24. Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2001;82:223-228. (Pubitemid 32730595)
25. Shalin SC, Lyle S, Calonje E, et al. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56:133-147.
26. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition - Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers. 2004;20:269-276. (Pubitemid 40164099)
27. Plaschke J, Engel C, Kruger S, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the german hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol. 2004;22:4486-4494. (Pubitemid 41185114)
28. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135:419-428.
29. Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet. 2007;71:483-498. (Pubitemid 46838526)
30. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816-819. (Pubitemid 23167612)
31. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812-816. (Pubitemid 23167611)
32. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558-561. (Pubitemid 23186645)
33. Baudhuin LM, Burgart LJ, Leontovich O, et al. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer. 2005;4:255-265. (Pubitemid 41242196)
34. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424-425.
35. Wijnen JT, Vasen HF, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med. 1998;339:511-518. (Pubitemid 28384884)
36. Syngal S, Fox EA, Eng C, et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet. 2000;37:641-645.
37. De Leon MP, Pedroni M, Benatti P, et al. Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut. 1999;45:32-38. (Pubitemid 29301842)
38. Jass JR. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J Gastroenterol. 2006;12:4943-4950. (Pubitemid 44323261)
39. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979-1985. (Pubitemid 40570891)
40. Mueller-Koch Y, Vogelsang H, Kopp R, et al. Hereditary nonpolyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut. 2005;54:1733-1740. (Pubitemid 41697672)
41. Dove-Edwin I, de Jong AE, Adams J, et al. Prospective results of surveillance colonoscopy in dominant familial colorectal cancer with and without Lynch syndrome. Gastroenterology. 2006;130:1995-2000. (Pubitemid 43816950)
42. Valle L, Perea J, Carbonell P, et al. Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. J Clin Oncol. 2007;25:781-786. (Pubitemid 350002877)
43. Llor X, Pons E, Xicola RM, et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res. 2005;11:7304-7310. (Pubitemid 41507688)
44. Lindor NM. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. Surg Oncol Clin N Am. 2009;18:637-645.
45. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-268. (Pubitemid 38256271)
46. Thomas BC, Thibodeau SN, Lindor NM. Clinical Significance of Tumor Microsatellite Instability and Immunohistochemistry for Mismatch Repair Deficiency in Colorectal Cancers. Curr Colorectal Cancer Report. 2005;1:103-109.
47. Vasen HF, Boland CR. Progress in genetic testing, classification, and identification of Lynch syndrome. JAMA. 2005;293:2028-2030. (Pubitemid 40570898)
48. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986-1994. (Pubitemid 40570892)
49. Kakar S, Burgart LJ, Thibodeau SN, et al. Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. Cancer. 2003;97:1421-1427. (Pubitemid 36297771)
50. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998;58:3455-3460. (Pubitemid 28371090)
51. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol. 2009;16:405-417.
52. Menigatti M, Di Gregorio C, Borghi F, et al. Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes Cancer. 2001;31:357-361. (Pubitemid 32622712)
53. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 2003;63:5209-5212. (Pubitemid 37139829)
54. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004;41:664-668. (Pubitemid 39208606)
55. Bouzourene H, Hutter P, Losi L, et al. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam Cancer. 2010;9:167-172.
56. McGivern A, Wynter CV, Whitehall VL, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer. 2004;3:101-107. (Pubitemid 40645891)
57. Bettstetter M, Dechant S, Ruemmele P, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res. 2007;13:3221-3228. (Pubitemid 46944905)
58. Hitchins MP, Ward RL. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorctal cancer. J Med Genet. 2009;46:793-802.
59. Pino MS, Mino-Kenudson M, Wildemore BM, et al. Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J Mol Diagn. 2009;11:238-247.
60. Wullenweber HP, Sutter C, Autschbach F, et al. Evaluation of Bethesda guidelines in relation to microsatellite instability. Dis Colon Rectum. 2001;44:1281-1289. (Pubitemid 32845905)
61. Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer. 2005;4:211-218. (Pubitemid 41242189)
62. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009;41:112-117.
63. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer. 2009;48:737-744.
64. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829-834. (Pubitemid 30243745)
65. Stupart DA, Goldberg PA, Algar U, et al. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis. 2009;11:126-130.
66. Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009;10:400-408.
67. Koornstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in lynch syndrome: is it time for surveillance? Lancet Oncol 2008;9:901-905.
68. Parry S, Win F, Marcrae B, et al. abstr 3515. J Clin Oncol. 2010;28.
69. De Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut. 2003;52:1752-1755.
70. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261-269. (Pubitemid 43113031)
71. Nielsen M, Franken PF, Reinards TH, et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet. 2005;42:e54.
72. Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology. 2004;127:9-16. (Pubitemid 38962269)
73. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 2003;348:791-799. (Pubitemid 36245755)
74. Sampson JR, Dolwani S, Jones S, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet. 2003;362:39-41. (Pubitemid 36835819)
75. Isidro G, Laranjeira F, Pires A, et al. Germline MUTYH (MYH) mutations in portuguese individuals with multiple colorectal adenomas. Hum Mutat. 2004;24:353-354.
76. Holter S, Gallinger S. MUTYH-Associated Polyposis. In: Potter JD, Lindor NM, eds. Genetics of Colorectal Cancer. New York, NY: Springer Science; 2009.
77. Lindor NM. Hereditary colorectal cancer: MYH-associated polyposis and other newly identified disorders. Best Pract Res Clin Gastroenterol. 2009;23:75-87.
78. Fleischmann C, Peto J, Cheadle J, et al. Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. Int J Cancer. 2004;109:554-558. (Pubitemid 38339646)
79. Riegert-Johnson DL, Johnson RA, Rabe KG, et al. The value of MUTYH testing in patients with early onset microsatellite stable colorectal cancer referred for hereditary nonpolyposis colon cancer syndrome testing. Genet Test. 2007;11:361-365.
80. Boparai KS, Dekker E, Van Eeden S, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology. 2008;135:2014-2018.
81. Mensink KA, Jass J, Lindor NM. Juvenile polyposis. In: Potter J, Lindor NM, eds. Genetics of Colorectal Cancer. New York: Springer; 2009:199-206.
82. Lipton L, Halford SE, Johnson V, et al. Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res. 2003;63:7595-7599. (Pubitemid 37466679)
83. Jenkins MA, Croitoru ME, Monga N, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev. 2006;15:312-314. (Pubitemid 43342180)
84. Aretz S, Uhlhaas S, Goergens H, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer. 2006;119:807-814. (Pubitemid 44051443)
85. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009;137:1976-1985. [e1-10].
86. Poulsen ML, Bisgaard ML. MUTYH Associated Polyposis (MAP). Curr Genomics. 2008;9:420-435.
87. Lipton L, Tomlinson I. The genetics of FAP and FAP-like syndromes. Fam Cancer. 2006;5:221-226. (Pubitemid 44453852)
88. De Ferro SM, Suspiro A, Fidalgo P, et al. Aggressive phenotype of MYH-associated polyposis with jejunal cancer and intra-abdominal desmoid tumor: report of a case. Dis Colon Rectum. 2009;52:742-745.
89. Croitoru ME, Cleary SP, Di Nicola N, et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst. 2004;96:1631-1634. (Pubitemid 39534887)
90. Eliason K, Hendrickson BC, Judkins T, et al. The potential for increased clinical sensitivity in genetic testing for polyposis colorectal cancer through the analysis of MYH mutations in North American patients. J Med Genet. 2005;42:95-96. (Pubitemid 40187129)
91. Bouguen G, Manfredi S, Blayau M, et al. Colorectal adenomatous polyposis Associated with MYH mutations: genotype and phenotype characteristics. Dis Colon Rectum. 2007;50:1612-1617. (Pubitemid 47583366)
92. Van Puijenbroek M, Nielsen M, Tops CM, et al. Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G >T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. Clin Cancer Res. 2008;14:139-142. (Pubitemid 351377988)